Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
More News related to REGN
- Regeneron Announces Presentation at the 21st Annual Piper Jaffray Healthcare Conference
- Merriman Curhan Ford Reiterates a 'Buy' on Regeneron (REGN); Raising Target Range
- Morning Movers 11/11: NCST, SMI, MSN, CHLN, NLST, REGN Higher; TGIC, STS, CLWR, STV, MHR, MBLX Lower
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
More News related to SNY
- New GoMeals(TM) iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
- Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
More News related to Corporate News
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
Sanofi-aventis will increase its annual funding commitment from $100M to $160 million beginning in 2010, and the research funding will now extend through 2017. The companies aim to advance an average of four to five antibodies into clinical development each year. In addition to its VelocImmune(®) technology, Regeneron will contribute to the collaboration its next generation technologies related to antibody generation.
Sanofi-aventis has an option to extend the discovery program for up to an additional three years for further antibody development and preclinical activities. The amendments announced today do not change the financial terms of the November 2007 agreement governing the development and commercialization of antibody drug candidates arising from the discovery collaboration.
[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
